Hormonal Contraceptive Market

A Nexplanon rod measures 4 cm by 2 mm, yet it holds 68 mg of etonogestrel and releases about 60 to 75 micrograms a day in weeks 5 and 6, falling to 15 to 20 micrograms by year five (Nexplanon summary of product characteristics). Hormonal contraceptives are medicines that prevent pregnancy by delivering a progestin, alone or with an estrogen, through a pill, injection, implant, intrauterine system, patch or vaginal ring. The hormonal contraceptive market covers manufacturer revenue from all six delivery formats. Douglas Insights puts it at USD 19.43 billion in 2025 and USD 27.96 billion in 2035, a revenue CAGR of 3.70%, because 268.6 million user-years at an average realised USD 72.35 each equal USD 19.43 billion. Organon reported Nexplanon sales of USD 921 million for 2025 in results released on 12 February 2026 (Organon full-year 2025 results). The study belongs to our women’s health therapeutics coverage and follows the Douglas Insights research methodology.

Why are hormonal contraceptive user-years rising 1.62% a year while birth rates fall?

Hormonal contraceptive user-years grow 1.62% a year to 2035, from 268.6 million to 315.4 million. Longer-acting implants and intrauterine systems, nonprescription pills and unmet need in Asia and Africa add users faster than falling fertility removes them. Douglas Insights splits that volume leg into three parts.

Unmet need adds 0.71 points. The United Nations counted 922 million women of reproductive age, or their partners, using contraception in 2019, and 842 million of them used a modern method (UN Contraceptive Use by Method 2019). The gap between those two figures, 80 million women on traditional methods, is the first pool a hormonal pill or injectable converts. Each 1% of that pool moved to a hormonal method adds about 0.8 million user-years.

Long-acting methods add 0.52 points. The same UN booklet counted 23 million implant users and 74 million injectable users in 2019, against 151 million on the pill (United Nations). A Nexplanon rod is licensed for 5 years of use, so one insertion converts into five user-years without a refill decision. Douglas Insights expects subdermal implants to grow 5.36% a year, the fastest of the five hormonal contraceptive segments.

Nonprescription access adds 0.39 points. The FDA approved Opill, a 0.075 mg norgestrel tablet, as the first nonprescription daily oral contraceptive in the United States on 13 July 2023 (FDA). Pharmacy, grocery and online sale removes the clinic visit that stops many women from starting a progestin-only pill. Douglas Insights counts roughly 1.1 million extra US user-years by 2035 from shelf access alone.

Hormonal intrauterine systems ride the same long-acting shift. The UN counted 159 million intrauterine device users in 2019, and most of that base still uses copper devices (UN data booklet). Douglas Insights assumes 0.9% of copper users switch to a levonorgestrel system each year, which lifts hormonal intrauterine systems at 4.71% a year. Bayer’s Mirena family grew 22.9% in the third quarter of 2025 on an adjusted basis, a sign that demand for hormonal devices outpaces pills (Bayer).

Asia Pacific supplies most of the unmet-need points. Douglas Insights places 0.44 of the 0.71 unmet-need points in Asia Pacific and 0.19 in the Middle East and Africa, where injectables at USD 9 to USD 64 a year are the usual first hormonal method.

Together the three parts sum to 1.62 points: 0.71 plus 0.52 plus 0.39. Format choice, not population, is the engine. The hormonal contraceptive buyer of 2035 is more likely to hold a rod or an intrauterine system than a 28-day blister pack.

What headwinds hold back hormonal contraceptive revenue in the United States?

US access restrictions, patent expiry on implant rods in 2027 and safety litigation over injectables are the three headwinds on hormonal contraceptive revenue. Together they remove about 0.92 points from the volume leg in our slower case, which drops 2035 value to USD 24.31 billion.

US policy is the sharpest. Organon said Nexplanon fell 9% in the United States in 2025, where access had been restricted by policy since early 2025, and that fourth-quarter Nexplanon sales fell to USD 211 million from USD 258 million (Organon). Douglas Insights removes 0.38 points of volume for North America in the slower case.

Patent expiry follows. Organon flags the expiration of the Nexplanon rod patents in 2027 in its 2025 results (Organon results). Generic implants would lift units but cut realised price; our slower case trims the price leg from 2.05% to 1.31%, removing 0.74 points of price.

Safety litigation on injectable contraceptives is the third drag. More than 1,000 women have sued Pfizer over meningioma risk linked to Depo-Provera, and the injectable label now carries a meningioma warning. Douglas Insights removes 0.21 points of injectable volume in the slower case, the smallest of the three hormonal contraceptive restraints.

Which hormonal contraceptive format makes the money, pills or long-acting devices?

Oral contraceptive pills make the money, with 51.3% of 2025 hormonal contraceptive revenue, or USD 9.97 billion. The pill counted 151 million users in 2019 and still leads in every region, but subdermal implants grow fastest at 5.36% a year.

Oral contraceptive pills hold USD 9.97 billion in 2025 and grow 3.04% to USD 13.45 billion, because daily pills are the cheapest entry point and nonprescription supply widens reach. Hormonal intrauterine systems account for USD 3.05 billion, a 15.7% share, and grow 4.71% a year, since one levonorgestrel device covers several years of use. Injectable contraceptives contribute USD 2.49 billion, or 12.8%, and grow 3.38%, held back by meningioma litigation in the United States. Subdermal implants reach USD 2.25 billion, an 11.6% share, and form the fastest segment at 5.36% a year because a single rod delivers five years of protection. Patches and vaginal rings add USD 1.67 billion, or 8.6%, growing 4.43% on weekly and monthly dosing.

By 2035 the long-acting share climbs. Implants and intrauterine systems together hold 27.3% of 2025 hormonal contraceptive value and rise toward 31% by 2035 in our model.

Where do hormonal contraceptives sell, and why does Asia Pacific grow fastest?

North America leads hormonal contraceptive revenue with USD 6.59 billion in 2025, about 33.9% of value, because US realised prices are the highest. Asia Pacific grows fastest at 5.13% a year, as public programmes move women from traditional methods to pills, injectables and implants.

North America moves from USD 6.59 billion to USD 8.74 billion at 2.87%, slowed by the access restrictions Organon describes. Europe rises from USD 4.70 billion to USD 6.46 billion at 3.22%, with branded pills and rings priced under national reimbursement. Asia Pacific climbs from USD 4.88 billion to USD 8.04 billion at 5.13%, the fastest hormonal contraceptive region, because the largest pool of women still using traditional methods lives there. Latin America grows from USD 1.83 billion to USD 2.87 billion at 4.61% on injectable and implant programmes. The Middle East and Africa holds USD 1.44 billion in 2025 and reaches USD 1.85 billion at 2.53%, because donor-funded injectables and implants sell at the lowest prices in our model.

The wildcard is donor funding. A cut in international family planning budgets would lower Middle East and Africa hormonal contraceptive volume faster than any price change could offset.

Which companies supply hormonal contraceptives, and how concentrated is competition?

Douglas Insights estimates the top three hormonal contraceptive suppliers, Bayer, Organon and Pfizer, hold 38.6% of 2025 value. The anchor is Organon’s disclosed USD 921 million of Nexplanon sales, about 4.7% of the USD 19.43 billion total on its own. Generic pill makers share the rest.

Organon and Bayer in long-acting methods

Organon builds its position on the Nexplanon implant and its Implanon NXT twin: USD 921 million of 2025 sales against USD 963 million in 2024, within a women’s health franchise of USD 1.75 billion (Organon). Bayer builds its position on the Mirena family of levonorgestrel intrauterine systems, whose sales rose 22.9% on a currency and portfolio adjusted basis in the third quarter of 2025, helped by a special US order (Bayer third-quarter 2025 release).

Pfizer, Perrigo, Mayne Pharma and Gedeon Richter

Pfizer supplies the Depo-Provera injectable, now sold with a meningioma warning. Perrigo owns Laboratoire HRA Pharma, the holder of the Opill approval, which gives it the only US nonprescription daily pill (FDA). Mayne Pharma grew NEXTSTELLIS net sales 41% to USD 42.5 million in the year to 30 June 2025, inside a women’s health segment of USD 115.5 million (Mayne Pharma FY25 results). Gedeon Richter, which reported HUF 914 billion of total 2025 revenue, is the sixth supplier we track.

Shares are modelled, not reported, and anchored on disclosed figures where they exist.

How much do buyers pay per user-year for each hormonal contraceptive method?

Buyers pay an average realised USD 72.35 per hormonal contraceptive user-year in 2025, by Douglas Insights estimate. Bands run from about USD 9 for donor-procured injectables to more than USD 160 for a branded US implant year. Price rises 2.05% a year to USD 88.63 by 2035.

Douglas Insights sets these realised price bands per user-year in 2025: generic oral pills USD 31 to USD 58, branded pills in the United States USD 140 to USD 210, injectables USD 9 to USD 64, implants USD 18 to USD 185 per year of protection, and hormonal intrauterine systems USD 22 to USD 170 per year. The spread reflects channel: public tenders in Asia and Africa pay a fraction of US pharmacy prices.

Long-acting methods carry the highest hormonal contraceptive price per insertion but the lowest per year in donor programmes, because a five-year implant spreads one purchase across five user-years.

What does nonprescription norgestrel change for hormonal contraceptive pill demand?

Nonprescription norgestrel adds about 1.1 million US hormonal contraceptive user-years by 2035 in our model, or 0.39 points of global volume growth. Opill, approved on 13 July 2023, removed the prescription step for one 0.075 mg progestin-only pill.

The FDA said the timeline for availability and price is determined by the manufacturer, and that Opill should be taken at the same time every day (FDA Opill approval). That daily-timing rule is the main limit: a progestin-only pill gives less room for a late dose than a combined pill. Douglas Insights expects shelf sales to pull younger users first, so the oral pill segment holds 51.3% of hormonal contraceptive value in 2025 and still about 48% in 2035.

What could change the hormonal contraceptive forecast for 2035?

The 2035 hormonal contraceptive outcome spans USD 24.31 billion in a slower case to USD 31.94 billion in a faster case, with our base at USD 27.96 billion. Generic implants after the 2027 rod patent expiry and US access policy decide the spread.

The slower case assumes US restrictions persist and generic rods arrive after 2027 (Organon). The faster case assumes nonprescription supply spreads beyond the July 2023 Opill approval and long-acting methods gain share. Adding one point to user-year growth lifts 2035 hormonal contraceptive value by USD 2.88 billion. Published forecasts sit between 3.6% and 4.5% a year; our 3.70% lies near the bottom because US volume shrank in 2025.

Which regulation and labelling rules govern hormonal contraceptive launches?

Prescription status is the main hormonal contraceptive regulation: only 1 daily pill, Opill, is approved for US nonprescription sale. Every other pill, injectable, implant and intrauterine system still needs a prescriber, and implants also need a trained inserter.

The Nexplanon product information requires removal no later than five years after insertion and lists 15 mg of barium sulphate in the core, so the rod shows on X-ray for location (Nexplanon SmPC). In the United States, the FDA approved a meningioma warning for Depo-Provera in December 2025 after earlier denying it, according to Pfizer. Organon notes that US policy has restricted Nexplanon access since early 2025 (Organon).

Douglas Exclusive: the Hormonal Contraceptive User-Year Ledger

The Hormonal Contraceptive User-Year Ledger is a Douglas Insights model built from 14 inputs: 9 sourced figures from the UN, FDA, Organon, Bayer and Mayne Pharma, plus 5 regional price assumptions of our own. It converts method users into user-years and revenue, and it puts 2025 hormonal contraceptive volume at 268.6 million user-years.

The finding is a value gap. Injectables carry 19.2% of hormonal contraceptive user-years but 12.8% of value, while patches and rings carry 3.5% of user-years and 8.6% of value. Price, not volume, sets the revenue ranking.

What does the hormonal contraceptive market include, and what sits outside?

The hormonal contraceptive market spans 5 product segments and excludes copper intrauterine devices, condoms and emergency contraception. Those exclusions apply to the USD 19.43 billion total for 2025 and the USD 27.96 billion total for 2035.

The study tracks oral contraceptive pills, hormonal intrauterine systems, injectable contraceptives, subdermal implants, and patches and vaginal rings. It covers combined and progestin-only hormones, three channels (retail pharmacy, hospital and clinic, public and donor programmes) and five regions. Menstrual disorders treated with hormones are covered in our Amenorrhea Market report, and the wider medicines industry is sized in the Pharmaceutical Drug Market study.

What methodology turns 268.6 million hormonal contraceptive user-years into revenue?

The model multiplies 268.6 million hormonal contraceptive user-years by a realised USD 72.35 each, giving USD 19.43 billion for 2025. Volume then grows 1.62% a year and price 2.05%, which lands at USD 27.96 billion in 2035 across five regions.

Inputs: 5 regional models, 5 method segments, 14 ledger inputs and 4 published CAGRs read for comparison. Arithmetic: 268.6 million times USD 72.35 equals USD 19.43 billion. Growth: 1.0162 times 1.0205 gives 3.70% a year, and 315.4 million user-years times USD 88.63 gives USD 27.96 billion.

Cross-check one: Organon’s USD 921 million of Nexplanon sales sits against our USD 2.25 billion implant segment, a 40.8% share for one brand. Cross-check two: the UN base of 248 million pill, injectable and implant users in 2019 grows to our 240.2 million user-years for those three methods once part-year use is netted. Regions sum to USD 19.43 billion in 2025 and USD 27.96 billion in 2035; the five segments sum to USD 28.13 billion in 2035, within 0.7% of the total.

Sources

1. United Nations Contraceptive Use by Method 2019 data booklet (2019)
2. US Food and Drug Administration FDA approves first nonprescription daily oral contraceptive (2023)
3. Organon Fourth quarter and full year 2025 results (2026)
4. electronic medicines compendium Nexplanon 68 mg implant summary of product characteristics (2025)
5. Bayer Bayer confirms 2025 group outlook (2025)
6. Mayne Pharma (ASX) FY25 results (2025)